EUVIMEDEUVIMED entdecken
Crossref

Berberine in traditional Chinese medicine: Modulating gut microbiota for gout management - mechanisms and clinical perspectives

Guoming Wang

Pakistan Journal of Pharmaceutical Sciences · 21.11.2026

DOI: 10.36721/pjps/2026.40.15219.1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pakistan Journal of Pharmaceutical Sciences, online erschienen am 21.11.2026. Verfasst von Guoming Wang. Die Arbeit nennt 95 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gout, a metabolic inflammatory arthritis driven by hyperuricemia, has rising global prevalence linked to high-purine and high-fructose diets. Gut dysbiosis, characterized by depleted beneficial microbes and overgrown pathogenic strains, disrupts uric acid (UA) excretion and exacerbates systemic inflammation, serving as a core pathological driver of gout. Conventional Western anti-gout drugs only relieve transient symptoms and carry severe side effects, whereas berberine (BBR), a bioactive alkaloid from traditional Chinese medicine (TCM), exerts multi-target anti-gout activity via gut microbiota regulation; however, its integrated intestinal mechanisms remain unsystematically summarized. This review elucidates the multi-pathway mechanisms through which BBR ameliorates gout by remodeling gut microbiota homeostasis and discusses its clinical translational prospects for gout management. This review retrieved English (PubMed, Web of Science, Scopus, EMBASE) and Chinese (CNKI, Wanfang) databases for peer-reviewed in vitro, animal and clinical studies published up to December 2024, combining gut microbiota, UA metabolism and berberine-related keywords; case reports, abstracts and duplicate papers were excluded. BBR restores intestinal microecology by elevating beneficial bacteria (Lactobacillus, Akkermansia, Bifidobacterium) and suppressing pro-inflammatory pathogens. It boosts butyrate production, upregulates intestinal ABCG2 to accelerate UA fecal excretion, and directly inhibits xanthine oxidase to reduce UA synthesis. Gut microbiota biotransforms BBR into DHB, OBR and other derivatives with higher bioavailability; these metabolites further inhibit renal UA reabsorption and block NLRP3 inflammasome activation to lower IL-1β/IL-18. The bidirectional BBR-microbiota interaction creates a positive feedback loop that amplifies hypouricemic and anti-inflammatory effects. BBR achieves comprehensive gout intervention via gut microbiota-centered multi-target regulation, representing a promising TCM-derived therapeutic strategy. Restricted oral bioavailability and insufficient large-scale human clinical data currently limit its clinical application; novel delivery systems, probiotic combination therapy and long-term clinical trials are required to advance its translational use in gout treatment.

Zitieren

APA

Wang, G. (2026). Berberine in traditional Chinese medicine: Modulating gut microbiota for gout management - mechanisms and clinical perspectives. Pakistan Journal of Pharmaceutical Sciences. https://doi.org/10.36721/pjps/2026.40.15219.1

Vancouver

Wang G. Berberine in traditional Chinese medicine: Modulating gut microbiota for gout management - mechanisms and clinical perspectives. Pakistan Journal of Pharmaceutical Sciences. 2026. doi:10.36721/pjps/2026.40.15219.1

BibTeX
@article{Wang2026,
  author = {Wang, Guoming},
  title = {Berberine in traditional Chinese medicine: Modulating gut microbiota for gout management - mechanisms and clinical perspectives},
  journal = {Pakistan Journal of Pharmaceutical Sciences},
  year = {2026},
  doi = {10.36721/pjps/2026.40.15219.1}
}
Kostenlos starten →